Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the answers.

The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same timeframe.

The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.

Shares of Sprinklr fell almost 9% in their market debut Wednesday, valuing the startup at $3.7B. Doximity sold well above range and ended the week even higher. Didi and Krispy Kreme are among in-focus, upcoming IPOs